We have not looked at the charts of Pfizer (PFE) since October 26 when we wrote that "Ahead of Pfizer's earnings Tuesday the charts suggest that investors are not positioned for an upside move." We also noted that "In this daily Point and Figure chart of PFE we can see a potential upside price target around $42 but also that a decline to $36.74 will start to weaken the picture."
More from Investing
The current version of the doughnut purveyor doesn't resemble the business that JAB Holdings acquired five years ago.
Let's check out the LLY charts amid FDA approval of the company's Alzheimer's drug.
Let's kick the tires and review the charts and indicators.
The technical signals for the maker of outdoor recreational equipment are bullish.
Hundreds of stocks will see volume spikes as the rebalancing occurs, though index funds have been accumulating these additions to the indices for a while.